Factors associated with human papillomavirus and meningococcal vaccination among adolescents living in rural and urban areas.

Adolescent CDC, Centers for Disease Control and Prevention CHIAS, Carolina HPV Immunization Attitudes and Beliefs Scale HPV, human papillomavirus Human papillomavirus IIS, immunization information system IRB, Institutional Review Board MCRI, Marshfield Clinic Research Institute MDH, Minnesota Department of Health MIIC, Minnesota Immunization Information Connection MenACWY, quadrivalent meningococcal conjugate vaccine Rural population Tdap, tetanus-diphtheria-acellular pertussis vaccine UIC, Urban Influence Codes Vaccinations WIR, Wisconsin Immunization Registry

Journal

Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 04 02 2022
revised: 20 05 2022
accepted: 24 05 2022
entrez: 27 6 2022
pubmed: 28 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

Studies have shown that adolescent vaccination rates with human papillomavirus (HPV) and quadrivalent meningococcal conjugate (MenACWY) vaccines are lower in rural areas of the U.S. than in urban areas. We sought to determine factors associated with vaccine acceptance in these two settings. We conducted a cross-sectional survey of 536 parents or guardians of teens age 13 through 15 years in select rural and urban counties of Minnesota and Wisconsin. We collected information on demographic variables, receipt of adolescent vaccines, and attitudes toward HPV vaccine in particular. Multivariable logistic regression models were used to assess associations between covariates and outcomes of interest (HPV vaccine receipt and MenACWY receipt). Of the 536 respondents, 267 (50%) resided in a rural county. Most respondents were female (78%) and non-Hispanic White (88%). About half (52%) of teens of the surveyed parents received the three vaccines recommended specifically for adolescents: 90% received tetanus-diphtheria-acellular pertussis (Tdap), 84% received MenACWY, and 60% received one or more doses of HPV vaccine. Rural and urban parents surveyed differed on several covariates relating to teen's health services, parent's demographics, and household characteristics. Parent's perception of the importance that their healthcare providers placed on vaccination with HPV and MenACWY were independently associated with receipt of each of those vaccines (odds ratio [OR] 6.37, 95% confidence interval [CI] 2.90-13.96 and OR 2.15, 95% CI 1.07-4.31, respectively). Parents of vaccinated teens were less likely to report concerns about potential harm from the HPV vaccine or having heard stories about health problems caused by the HPV vaccine. Teen receipt of HPV vaccine and MenACWY appears to be influenced by parents' perception of vaccine importance, provider recommendations, and concerns regarding potential harm from the HPV vaccine. Continued education of providers and parents of the importance of adolescent vaccinations is warranted.

Sections du résumé

Background UNASSIGNED
Studies have shown that adolescent vaccination rates with human papillomavirus (HPV) and quadrivalent meningococcal conjugate (MenACWY) vaccines are lower in rural areas of the U.S. than in urban areas. We sought to determine factors associated with vaccine acceptance in these two settings.
Methods UNASSIGNED
We conducted a cross-sectional survey of 536 parents or guardians of teens age 13 through 15 years in select rural and urban counties of Minnesota and Wisconsin. We collected information on demographic variables, receipt of adolescent vaccines, and attitudes toward HPV vaccine in particular. Multivariable logistic regression models were used to assess associations between covariates and outcomes of interest (HPV vaccine receipt and MenACWY receipt).
Results UNASSIGNED
Of the 536 respondents, 267 (50%) resided in a rural county. Most respondents were female (78%) and non-Hispanic White (88%). About half (52%) of teens of the surveyed parents received the three vaccines recommended specifically for adolescents: 90% received tetanus-diphtheria-acellular pertussis (Tdap), 84% received MenACWY, and 60% received one or more doses of HPV vaccine. Rural and urban parents surveyed differed on several covariates relating to teen's health services, parent's demographics, and household characteristics. Parent's perception of the importance that their healthcare providers placed on vaccination with HPV and MenACWY were independently associated with receipt of each of those vaccines (odds ratio [OR] 6.37, 95% confidence interval [CI] 2.90-13.96 and OR 2.15, 95% CI 1.07-4.31, respectively). Parents of vaccinated teens were less likely to report concerns about potential harm from the HPV vaccine or having heard stories about health problems caused by the HPV vaccine.
Conclusion UNASSIGNED
Teen receipt of HPV vaccine and MenACWY appears to be influenced by parents' perception of vaccine importance, provider recommendations, and concerns regarding potential harm from the HPV vaccine. Continued education of providers and parents of the importance of adolescent vaccinations is warranted.

Identifiants

pubmed: 35755142
doi: 10.1016/j.jvacx.2022.100180
pii: S2590-1362(22)00040-7
pmc: PMC9218554
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100180

Subventions

Organisme : NCIRD CDC HHS
ID : U01 IP001093
Pays : United States

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Hum Vaccin Immunother. 2017 Aug 3;13(8):1844-1855
pubmed: 28605256
JAMA Pediatr. 2014 Jan;168(1):76-82
pubmed: 24276343
BMC Public Health. 2017 Oct 2;17(1):766
pubmed: 28969653
Vaccine. 2018 Jun 27;36(28):4126-4133
pubmed: 29793895
Acad Pediatr. 2016 Jan-Feb;16(1):42-9
pubmed: 26300368
JAMA Pediatr. 2018 May 7;172(5):e180016
pubmed: 29507952
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Pediatrics. 2016 Nov;138(5):
pubmed: 27940751
Sex Transm Dis. 2010 Apr;37(4):234-9
pubmed: 19940807
Vaccine. 2016 Feb 24;34(9):1187-92
pubmed: 26812078
J Adolesc Health. 2018 Feb;62(2):157-163
pubmed: 29248390
Prev Med. 2017 Feb;95:26-37
pubmed: 27932052
Pediatrics. 2020 Dec;146(6):
pubmed: 33199466
MMWR Morb Mortal Wkly Rep. 2021 Sep 03;70(35):1183-1190
pubmed: 34473682
Vaccine. 2016 Nov 11;34(47):5708-5723
pubmed: 27765379
Hum Vaccin Immunother. 2019;15(7-8):1776-1783
pubmed: 30570419
Vaccine. 2017 Feb 1;35(5):802-807
pubmed: 28063706
Vaccine. 2015 Nov 27;33 Suppl 4:D106-13
pubmed: 26615169
Hum Vaccin Immunother. 2019;15(7-8):1650-1655
pubmed: 30633622
Hum Vaccin Immunother. 2019;15(7-8):1465-1475
pubmed: 30779682
Soc Sci Med. 2009 Aug;69(3):475-80
pubmed: 19540642

Auteurs

Thomas G Boyce (TG)

Marshfield Clinic Research Institute, Marshfield, WI, USA.

Ben Christianson (B)

Minnesota Department of Health, St. Paul, MN, USA.

Kayla E Hanson (KE)

Marshfield Clinic Research Institute, Marshfield, WI, USA.

Denise Dunn (D)

Minnesota Department of Health, St. Paul, MN, USA.

Elizabeth Polter (E)

Minnesota Department of Health, St. Paul, MN, USA.

Jeffrey J VanWormer (JJ)

Marshfield Clinic Research Institute, Marshfield, WI, USA.

Charnetta L Williams (CL)

Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Edward A Belongia (EA)

Marshfield Clinic Research Institute, Marshfield, WI, USA.

Huong Q McLean (HQ)

Marshfield Clinic Research Institute, Marshfield, WI, USA.

Classifications MeSH